Recent Updates
Recently added Catalysts
INM Positive Sentiment Score: 65/100

NASDAQ: INM Suite 310-815 W. Hastings St. Vancouver, BC, Canada V6C 1B4 Tel: +1.604.669.7207 Email: info@inmedpharma.com www.inmedpharma.com InMed to Participate in Fireside Chat with Water Tower Research on

Key Takeaway: InMed Pharmaceuticals Inc. will participate in a Water Tower Research Fireside Chat on May 23, 2023, focusing on the company's progress and engagement with investors. Eric A. Adams, the CEO, will lead discussions highlighting the importance of their BayMedica subsidiary and upcoming catalysts. The event is open to all investors, promoting transparency and communication. InMed also cautions that forward-looking statements carry inherent risks and uncertainties that could impact outcomes.

Market Sentiment Analysis

POSITIVE FACTORS

  • InMed Pharmaceuticals will participate in a prominent fireside chat, highlighting its engagement with investors.
  • The event will cover important topics regarding the company's growth and its BayMedica subsidiary.
  • Open access to the event allows for broader investor participation, enhancing communication and transparency.

CONCERNS & RISKS

  • The company acknowledges the presence of risks and uncertainties that could affect future performance.
  • There is a cautionary note indicating that forward-looking statements may differ from actual results.
  • The mention of risks tied to the growth of the BayMedica subsidiary suggests potential challenges ahead.

Full Press Release Details

InMed to Participate in Fireside Chat with Water
Tower Research on May 23, 2023 at 1pm ET
May 18, 2023 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM),
a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs,
today announce Eric A. Adams, CEO of InMed, will be participating in the Water Tower Research Fireside Chat Series on May 23, 2023, at
This event is open access for all investors
to participate. Topics will include:
Interested parties can register for the
event at the link below. Replays of the webcast will also be available after the event.
PLEASE REGISTER HERE
InMed Pharmaceuticals is a global leader
in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical programs targeting
the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches
to produce cannabinoids for various market sectors. For more information, visit www.inmedpharma.com.
About Water Tower Research
Water Tower Research is a shareholder communication and engagement platform powered by senior industry experts with significant Wall Street
experience. We create, deliver, and maintain the information flow required to build and preserve relationships with every stakeholder
and potential investor. Our foundation is built on Wall Street veterans using open digital distribution strategies that are accessible
by everyone. "Research for the Other 99% " opens the door to reach a much broader and diverse set of investors while
helping to strengthen overall communications, transparency, and engagement. For more information, visit https://www.watertowerresearch.com/home.
Vice President, Investor Relations
and Corporate Communications
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning
of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to
a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
Forward-looking information in this news release includes statements about: the importantance of the BayMedica subsidiary to the Company's
growth; upcoming catalysts for the Company.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties
facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities
and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified
in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results,
events or developments, except as required by law.

Frequently Asked Questions

When is InMed's participation in the Fireside Chat?

InMed's Fireside Chat is scheduled for May 23, 2023, at 1pm ET.

Who will represent InMed in the Fireside Chat?

Eric A. Adams, the CEO of InMed, will participate in the chat.

Is registration required for the event?

Yes, interested parties can register to participate in the event.

What topics will be discussed during the event?

The chat will cover various topics related to InMed's developments and strategies.

Where can I find more information about InMed?

For more information, visit InMed's official website at www.inmedpharma.com.

Last updated: May 19, 2023